December 10, 2019
Sanofi announced a major strategy shift today that will end the pharma’s diabetes and cardiovascular R&D efforts in favor of a reinvigorated focus on growing its immunology and vaccine businesses.
Among the fallout of this new game plan is Onduo, the pharma’s diabetes management joint venture with Verily that the two companies invested $500 million into back in 2016, according to the company’...
December 3, 2019
Dexcom continuous glucose monitor users and their caregivers found themselves in the dark this weekend when a key monitoring feature ceased to function with little to no warning.
The feature, called Dexcom Follow, transmits an alert when a CGM user’s blood sugar reaches a dangerous level and is often used by parents monitoring their children’s condition. When unexpected issues brought down the...
November 21, 2019
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday.
To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...
November 20, 2019
The US Department of Veterans Affairs recently announced a regional rollout that it will make a connected device for diabetic foot ulcer detection available to veterans across the country as of December 1.
The platform, developed by Somerville, Massachusetts-based Podimetrics, is already being used at 15 of the department’s medical centers, and according to the VA will also be included in an...
November 15, 2019
Livongo is touting new data regarding the efficacy of its device-and-coaching disease management platform, this time among those using its Livongo for Hypertension and Livongo for Diabetes products together.
The results, which are set to be formally presented this weekend at the American Heart Association Scientific Sessions 2019, identified significant decreases in hypertensive blood pressure as...
November 14, 2019
Digital chronic care platform Omada is deepening its relationship with Blue Cross and Blue Shield of Minnesota (Blue Cross), inking a new deal that provides the insurer’s commercial plan members access to the startup’s Type 2 diabetes care platform.
As part of yesterday’s news, Blue Cross also announced it would be making a strategic investment in Omada; however, the actual value of this...
November 11, 2019
Ninety-eight percent of veterans with Type 2 diabetes enrolled in Virta’s digital diabetes management program reduced or controlled their estimated HbA1c level after 90 days, according to new results from a pilot conducted by the U.S. Department of Veterans Affairs and Virta Health.
The pilot, which included a total of 104 patients, found that 84% of patients enrolled achieved an estimated HbA1c...
October 29, 2019
Life insurer John Hancock has unveiled a new wearable program dubbed Aspire aimed at helping its members with diabetes manage the condition. The program was born out of a partnership with Verily and digital diabetes care platform Onduo.
Users of the new platform can access diabetes coaching via Onduo’s virtual clinic. The program also has fiscal rewards. According to the company, members using...
October 24, 2019
A study published in the New England Journal of Medicine found that Type 1 diabetes patients using a closed-loop system spent a higher percentage of time in their target glucose range than their peers using a sensor-augmented pump.
Researchers also found that the glycated hemoglobin level of patients using the closed-loop system improved during the study. Conversely, on average patients in the...
October 11, 2019
It’s little secret that chronic conditions are a heavy burden on the healthcare system. Diabetes, heart disease, obesity and others can stick with a patient for decades, often leading to increased spending on disease management programs and costly visits when those efforts aren’t making an impact.
What’s worse, many of the clinical advances of the past decade or so haven’t substantially moved the...